IFIT3 may be a potential therapeutic target for ischemic cardiomyopathy [63], and IFIT1 and IFIT5 are key genes that are used to predict treatment response in patients with microvascular disease in the early stage [64]. This evidence concerns the gene IFIT5 and ischemic cardiomyopathy.